165 related articles for article (PubMed ID: 30746211)
1. Membrane PD-L1 expression and soluble PD-L1 plasma levels in idiopathic pulmonary fibrosis-a pilot study.
Jovanovic D; Roksandic Milenkovic M; Kotur Stevuljevic J; Markovic J; Ceriman V; Kontic M; Skodric Trifunovic V
J Thorac Dis; 2018 Dec; 10(12):6660-6669. PubMed ID: 30746211
[TBL] [Abstract][Full Text] [Related]
2. PD-L1 Expression in Patients with Idiopathic Pulmonary Fibrosis.
Kronborg-White S; Madsen LB; Bendstrup E; Poletti V
J Clin Med; 2021 Nov; 10(23):. PubMed ID: 34884264
[TBL] [Abstract][Full Text] [Related]
3. Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis.
Karampitsakos T; Galaris A; Chrysikos S; Papaioannou O; Vamvakaris I; Barbayianni I; Kanellopoulou P; Grammenoudi S; Anagnostopoulos N; Stratakos G; Katsaras M; Sampsonas F; Dimakou K; Manali ED; Papiris S; Tourki B; Juan-Guardela BM; Bakakos P; Bouros D; Herazo-Maya JD; Aidinis V; Tzouvelekis A
Respir Res; 2023 Nov; 24(1):279. PubMed ID: 37964265
[TBL] [Abstract][Full Text] [Related]
4. IL-8 concurrently promotes idiopathic pulmonary fibrosis mesenchymal progenitor cell senescence and PD-L1 expression enabling escape from immune cell surveillance.
Yang L; Xia H; Gilbertsen A; Smith K; Racila E; Bitterman PB; Henke CA
Am J Physiol Lung Cell Mol Physiol; 2023 Jun; 324(6):L849-L862. PubMed ID: 37121574
[TBL] [Abstract][Full Text] [Related]
5. Soluble PD-L1 as a predictive biomarker in lung cancer: a systematic review and meta-analysis.
Cheng Y; Wang C; Wang Y; Dai L
Future Oncol; 2022 Jan; 18(2):261-273. PubMed ID: 34874185
[TBL] [Abstract][Full Text] [Related]
6. Soluble PD-L1 Is an Independent Prognostic Factor in Clear Cell Renal Cell Carcinoma.
Larrinaga G; Solano-Iturri JD; Errarte P; Unda M; Loizaga-Iriarte A; Pérez-Fernández A; Echevarría E; Asumendi A; Manini C; Angulo JC; López JI
Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33562338
[TBL] [Abstract][Full Text] [Related]
7. The role of PD-1/PD-L1 axis in idiopathic pulmonary fibrosis: Friend or foe?
Jiang A; Liu N; Wang J; Zheng X; Ren M; Zhang W; Yao Y
Front Immunol; 2022; 13():1022228. PubMed ID: 36544757
[TBL] [Abstract][Full Text] [Related]
8. Serum levels of soluble programmed death-ligand 1 (sPD-L1) in patients with primary central nervous system diffuse large B-cell lymphoma.
Cho I; Lee H; Yoon SE; Ryu KJ; Ko YH; Kim WS; Kim SJ
BMC Cancer; 2020 Feb; 20(1):120. PubMed ID: 32054467
[TBL] [Abstract][Full Text] [Related]
9. Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
Incorvaia L; Fanale D; Badalamenti G; Porta C; Olive D; De Luca I; Brando C; Rizzo M; Messina C; Rediti M; Russo A; Bazan V; Iovanna JL
Oncoimmunology; 2020 Oct; 9(1):1832348. PubMed ID: 33178494
[TBL] [Abstract][Full Text] [Related]
10. Soluble immune checkpoints CTLA-4, HLA-G, PD-1, and PD-L1 are associated with endometriosis-related infertility.
Santoso B; Sa'adi A; Dwiningsih SR; Tunjungseto A; Widyanugraha MYA; Mufid AF; Rahmawati NY; Ahsan F
Am J Reprod Immunol; 2020 Oct; 84(4):e13296. PubMed ID: 32593225
[TBL] [Abstract][Full Text] [Related]
11. Soluble PD-L1 Expression in Circulation as a Predictive Marker for Recurrence and Prognosis in Gastric Cancer: Direct Comparison of the Clinical Burden Between Tissue and Serum PD-L1 Expression.
Shigemori T; Toiyama Y; Okugawa Y; Yamamoto A; Yin C; Narumi A; Ichikawa T; Ide S; Shimura T; Fujikawa H; Yasuda H; Hiro J; Yoshiyama S; Ohi M; Araki T; Kusunoki M
Ann Surg Oncol; 2019 Mar; 26(3):876-883. PubMed ID: 30565045
[TBL] [Abstract][Full Text] [Related]
12. Pre-treatment serum levels of soluble programmed cell death-ligand 1 predict prognosis in patients with hepatitis B-related hepatocellular carcinoma.
Han X; Gu YK; Li SL; Chen H; Chen MS; Cai QQ; Deng HX; Zuo MX; Huang JH
J Cancer Res Clin Oncol; 2019 Feb; 145(2):303-312. PubMed ID: 30267213
[TBL] [Abstract][Full Text] [Related]
13. Inhibitor of PD-1/PD-L1: a new approach may be beneficial for the treatment of idiopathic pulmonary fibrosis.
Tan J; Xue Q; Hu X; Yang J
J Transl Med; 2024 Jan; 22(1):95. PubMed ID: 38263193
[TBL] [Abstract][Full Text] [Related]
14. Association between serum level soluble programmed cell death ligand 1 and prognosis in patients with non-small cell lung cancer treated with anti-PD-1 antibody.
Murakami S; Shibaki R; Matsumoto Y; Yoshida T; Goto Y; Kanda S; Horinouchi H; Fujiwara Y; Yamamoto N; Ohe Y
Thorac Cancer; 2020 Dec; 11(12):3585-3595. PubMed ID: 33108686
[TBL] [Abstract][Full Text] [Related]
15. Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas.
Zhang X; Liu L; Zhou S; Zhao K; Song Z; Hu G; Zhang T; Li Y; Qiu L; Li L; Qian Z; Meng B; Pan Y; Ren X; Wang X; Zhang H; Fu K
Hematol Oncol; 2019 Aug; 37(3):270-276. PubMed ID: 31074879
[TBL] [Abstract][Full Text] [Related]
16. Soluble forms of PD-L1 and PD-1 as prognostic and predictive markers of sunitinib efficacy in patients with metastatic clear cell renal cell carcinoma.
Montemagno C; Hagege A; Borchiellini D; Thamphya B; Rastoin O; Ambrosetti D; Iovanna J; Rioux-Leclercq N; Porta C; Negrier S; Ferrero JM; Chamorey E; Pagès G; Dufies M
Oncoimmunology; 2020 Nov; 9(1):1846901. PubMed ID: 33299657
[TBL] [Abstract][Full Text] [Related]
17. Soluble PD-L1 with PD-1-binding capacity exists in the plasma of patients with non-small cell lung cancer.
Takeuchi M; Doi T; Obayashi K; Hirai A; Yoneda K; Tanaka F; Iwai Y
Immunol Lett; 2018 Apr; 196():155-160. PubMed ID: 29366663
[TBL] [Abstract][Full Text] [Related]
18. Oxidative stress and inflammation parameters-novel biomarkers for idiopathic pulmonary fibrosis.
Roksandic Milenkovic M; Klisic A; Ceriman V; Kotur Stevuljevic J; Savic Vujovic K; Mirkov D; Gajic M; Ilic B; Dimic N; Samardzic N; Jovanovic D
Eur Rev Med Pharmacol Sci; 2022 Feb; 26(3):927-934. PubMed ID: 35179759
[TBL] [Abstract][Full Text] [Related]
19. [Expression of soluble programmed death-1, soluble programmed death ligand 1 proteins and immune status in patients with oral lichen planus].
Luo L; Shu M; Li S; Cai Y
Zhonghua Kou Qiang Yi Xue Za Zhi; 2015 Oct; 50(10):585-9. PubMed ID: 26757624
[TBL] [Abstract][Full Text] [Related]
20. [The content of the soluble forms PD-1 and PD-L1 in blood serum of patients with gastric cancer and their relationship with clinical and morphological characteristics of the disease.].
Gershtein ES; Ognerubov NA; Chang VL; Delektorskaya VV; Korotkova EA; Sokolov NY; Polikarpova SB; Stilidi IS; Kushlinskii NE
Klin Lab Diagn; 2020; 65(6):347-352. PubMed ID: 32459892
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
